Rhinomed Ltd
ASX:RNO
Rhinomed Ltd
ASX:RNO
Price:
0.04 AUD
Market Closed
Updated:
Apr 30, 2024
Rhinomed Ltd
Cash from Operating Activities
|
Rhinomed Ltd
Cash from Operating Activities Peer Comparison
Comparables:
MYX
NEU
BOT
PBP
C
CU6
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Rhinomed Ltd
ASX:RNO
|
Cash from Operating Activities
-AU$7.2m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-12%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Cash from Operating Activities
-AU$42.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cash from Operating Activities
AU$184.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
96%
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Cash from Operating Activities
-AU$10.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-29%
|
|
|
Probiotec Ltd
ASX:PBP
|
Cash from Operating Activities
AU$15.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
9%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Cash from Operating Activities
-AU$27.5m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Rhinomed Ltd's Cash from Operating Activities?
Cash from Operating Activities
-7.2m
AUD
-7.2m
AUD
Based on the financial report for Jun 30, 2023, Rhinomed Ltd's Cash from Operating Activities amounts to -7.2m AUD.
What is Rhinomed Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-12%
-12%
Over the last year, the Cash from Operating Activities growth was -25%. The average annual Cash from Operating Activities growth rates for Rhinomed Ltd have been -8% over the past three years , -13% over the past five years , and -12% over the past ten years .
You don't have any saved screeners yet
